Drug Trial Radar · NCT04663308
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
182
Actual
Start
Dec 18, 2020
Primary completion
Feb 20, 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Conditions
- Primary Sclerosing Cholangitis
Interventions
VolixibatDrug
Oral capsules, administered twice daily. Volixibat is an Ileal Bile Acid Transporter (IBAT) inhibitor.
PlaceboDrug
Capsules matched to study drug minus active substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in the daily itch scores using the Adult Itch Reported Outcome (Adult ItchRO) questionnaireTime frame: Baseline through to Week 28
Locations
103 sites in 14 countries. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Cedars Sinai Medical Center
Los Angeles, California
University of California, Davis
Sacramento, California
California Pacific Medical Center Research Institute
San Francisco, California
University of Colorado - Anschutz Medical Campus
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Florida Research Institute
Lakewood Rch, Florida
University of Miami - Schiff Center for Liver Diseases
Miami, Florida
Tampa General Hospital
Tampa, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Southern Therapy and Advanced Research LLC
Jackson, Mississippi
Northwell Health
Manhasset, New York
New York University Langone Health
New York, New York
Weill Cornell Medical College
New York, New York
Columbia University Medical Center - Presbyterian Hospital and Vanderbilt Clinic
New York, New York
University of Rochester Medical Center - Strong Memorial Hospital
Rochester, New York
Duke Health - Duke University Medical Center
Durham, North Carolina
Science 37, Inc (Remote-homebased Telemedicine)
Morrisville, North Carolina
Cleveland Clinic
Cleveland, Ohio
Einstein Healthcare Network - Einstein Medical Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Galen Medical Group
Hixson, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
The Liver Institute At Methodist Dallas Medical Center
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
Liver Associates of Texas
Houston, Texas
University of Utah Health Care
Salt Lake City, Utah
Bon Secours Liver Institution of Hampton Roads Mary Immaculate Hospital Office
Newport News, Virginia
Richmond Community Hospital LLC
Richmond, Virginia
University of Washington - Harborview Medical Center
Seattle, Washington
Liver Institute Northwest
Seattle, Washington
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Glenny Corp S.A.
Ciudad Autónoma Buenos Aires, Argentina
Hospital El Cruce
San Juan Bautista, Argentina
Royal Adelaide Hospital
Adelaide, Australia
Northern Health
Epping, Australia
Liverpool Hospital
Liverpool, Australia
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.